Inflammatory Myofibroblastic Tumor Refractory to Three Lines of ALK Inhibitors and Combination Immunotherapy
Creators
- 1. University of Miami Miller School of Medicine, Miami, FL, USA
- 2. Department of Pathology, University of Miami Miller School of Medicine, Miami, FL, USA
- 3. Department of Radiology, University of Miami Miller School of Medicine, Miami, FL, USA
- 4. Department of Medicine, Division of Medical Oncology, University of Miami Miller School of Medicine, Miami, FL, USA
Description
Abstract
Inflammatory myofibroblastic tumors (IMT) are spindle cell neoplasms with myofibroblastic differentiation and inflammatory infiltration that are typically benign in presentation but can present aggressively in rare circumstances. We herein report the case of a 17-year-old Jamaican female with metastatic IMT who initially presented to the emergency department in her hometown of Kingston, Jamaica with severe chest tightness. Due to severe hemoptysis in the emergency department, the patient underwent emergent right upper and middle lobectomy after initial radiological work-up showing a mixed density mass within the right upper lobe. Initial pathology done by a general pathologist interpreted immunohistochemical findings to be suggestive of histiocytic sarcoma. However, follow-up analysis by a sarcoma-specialized pathologist at our institution resulted in an interpretation of inflammatory myofibroblastic tumor. While typical treatment consists of surgical removal and chemotherapy, the aggressive presentation of this patient’s disease necessitated combinations of targeted therapies such as ALK inhibitors with immunotherapy
Notes
Files
IJCMC-5-178.pdf
Files
(1.3 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:8724f03e630ae0cbda22b1dbd31175cc
|
1.3 MB | Preview Download |
Additional details
Related works
- Is published in
- Journal article: https://www.boffinaccess.com/clinical-and-medical-cases/seiya-liu-ijcmc-5-178/IJCMC-5-178.pdf (URL)
- Journal article: https://www.boffinaccess.com/clinical-and-medical-cases/seiya-liu-ijcmc-5-178 (URL)
References
- Coffin CM, Hornick JL, Fletcher CDM. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including AL Kexpression in a typical and aggressive cases. Am J Surg Pathol.2007 Apr;31(4):509-520.
- Lovly CM, Gupta A, Lipson D, Otto G, Brenman T, et al. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov. 2014 Aug;4(8):889-895.
- Mosse YP, Voss SD, Lim MS, Rolland D, Minard CG, et al. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. J Clin Oncol. 2017Oct;35(28):3215-3221.
- Poyraz N, Yazar ME, Kilinc F, Korkkmaz C, et al. [Inflammatory myofibroblastic tumor of the lung: histopathology and imaging findings]. Tuberk Toraks. 2020 Sep;68(3):321-327.
- Fu GX, Xu CC, Yao NF, Gu JG, Jiang HL, et al. Inflammatory myofibroblastic tumor: A demographic, clinical and therapeutic study of 92 cases. Math Biosci Eng. 2019 Jul;16(6):6794-6804.
- Da M, Qian B, Mo X, Xu C, Wu H, et al. Inflammatory Myofibroblastic Tumors in Children: A Clinical Retrospective Study on 19 Cases. Front Pediatr. 2021 Jul;9:543078.
- Marino-Enriquez A, Wang WL, Roy A, Lopez-Terrada D, LazarAF, et al. Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK. Am J Surg Pathol. 2011 Jan;35(1):135-144.
- Hallberg B, Palmer RH. The role of the ALK receptor in cancerbiology. Ann Oncol. 2016 Sep;27Suppl 3:iii4-iii15.
- Di Ruscio V, Mastronuzzi A, Russo I, Neri M, Stracuzzi A, etal. Inflammatory Myofibroblastic Tumor of the Upper Airways Harboring a New TRAF3-ALK Fusion Transcript. Children(Basel). 2021 Jun;8(6):505.
- Yuan C, Ma MJ, Parker J, Mekhail TM. Metastatic Anaplastic Lymphoma Kinase-1 (ALK-1)-Rearranged Inflammatory Myofibroblastic Sarcoma to the Brain with Leptomeningeal Involvement: Favorable Response to Serial ALK Inhibitors: ACase Report. Am J Case Rep. 2017 Jul;18:799-804.